Le Lézard
Classified in: Health, Business
Subjects: SLS, LIC

Rain Forest International, Inc. Announces Revenues


CHINCHA ALTA, Peru, Feb. 15, 2019 /PRNewswire/ -- Rain Forest International, Inc. (the "Company") (OTC: RFII), announced today that the Company's wholly owned subsidiary, Rain Forest Nutraceuticals, Inc. ("Rain Forest") has achieved product sales in excess of $80,000 since being acquired by the Company in April of 2018.

The Company consummated a Share Exchange Agreement (the "SEA") with Rain Forest, a private corporation organized under the laws of the State of Nevada.  In accordance with the terms of the SEA, the Company acquired 100% of Rain Forest's shares in exchange for the issuance by the Company of 150,000,000 of its restricted common stock to the shareholders of Rain Forest resulting in Rain Forest becoming the wholly owned subsidiary of the Company.

Rain Forest entered into a master license agreement with UVdA S.A.C., a Peruvian third generation family business ("UVdA"), pursuant to which UVdA granted to Rain Forest an exclusive worldwide license and associated rights, excluding South America, to market and sell a line of nutraceutical products based on UVdA's exceptional amazon rain forest grape seed extracts and oils (the "Products").  UVdA is a successful company producing their premium Products with revenues in excess of $1,000,000 and net profits in excess of $400,000 in their last fiscal year.

Jose Veliz, President of Rain Forest states, "To date, my team and I have generated product sales in excess of $80,000, primarily in Germany, and we look forward to duplicating and surpassing the great results my family achieved in South America, to the rest of the world."

About Rain Forest International, Inc.:

Rain Forest International, Inc. (www.rainforestinternational.com), is a business opportunity company with a primary focus on working with and/or acquiring operational companies to work with for the purpose of enhancing shareholder value.  Through its wholly owned subsidiary Rain Forest Nutraceuticals, Inc., it markets and sells a line of nutraceutical products based on a premium grape seed extract from the Amazon Rain Forest.

Forward Looking Statements
Undue reliance should not be placed on forward looking statements in this press release.  This press release contains forward looking statements that involve risks and uncertainties.  Words such as "will", "anticipates", "believes", "plans", "goal", "expects", "future", "intends", and similar expressions are used to identify these forward looking statements.  Actual results could materially differ from those anticipated in these forward looking statements for many reasons.

SOURCE Rain Forest International, Inc.


These press releases may also interest you

at 14:50
The Huntington National Bank and its Lift Local Business program have been nationally recognized by the Consumer Bankers Association (CBA) with the 2024 Joe Belew Award. The award honors CBA member banks for their efforts to address pressing social...

at 14:47
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Innoviz Technologies Ltd. between April 21, 2021 and February 28, 2023, both dates inclusive (the "Class Period"), of the important May 14, 2024 lead...

at 14:30
Transaction in Own Shares 28 March, 2024 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? Shell plc (the ?Company') announces that on 28 March 2024 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according...

at 14:30
Southwest Airlines Co.  announces the acquisition of SAFFiRE Renewables, LLC (SAFFiRE) as part of the investment portfolio of its wholly owned subsidiary Southwest Airlines Renewable Ventures, LLC (SARV). SARV is dedicated to creating more...

at 14:28
Nuventive, the data-informed improvement companytm, today announced a partnership with D2L, a global learning technology company, to simplify student outcomes analysis and advancement. By linking reports from the D2L Brightspace learning management...

at 14:25
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and...



News published on and distributed by: